The mutational profile of 32 recurrently mutated genes in myeloid
malignancies was determined using an Illumina TruSeq Custom Amplicon
next-generation sequencing gene panel (Supplementary Table 2) and the TruSeq Amplicon 2.0
BaseSpace app workflow 51 (link) (Illumina, San
Diego, CA, USA). 31 inositide-specific point mutations and small indels (Supplementary Table 3)
were examined using the Ion Torrent S5 with an Ion AmpliSeq™ On-demand
Panel (Thermo Fisher Scientific,Whaltam, MA, USA). Sequencing alignment was
viewed by the Integrative Genomics Viewer Software (Broad Institute, Cambridge,
MA, USA) using the Human Genome Build 19 (Hg19) as the reference 52 (link). Further details can be found in the
Supplementary
Information
.